Prodotto aggiunto correttamente al carrello.

discount label
H-TPHPARIGL-OH
Visualizzare in 3D

Biosynth logo

H-TPHPARIGL-OH

Rif. 3D-PP45176

1mg
217,00 €
10mg
253,00 €
100mg
455,00 €
Consegna stimata in Stati Uniti, il Venerdì 27 Dicembre 2024

Informazioni sul prodotto

Nome:
H-TPHPARIGL-OH
Sinonimi:
  • NH2-Thr-Pro-His-Pro-Ala-Arg-Ile-Gly-Leu-OH
Descrizione:

Peptide H-TPHPARIGL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-TPHPARIGL-OH include the following: Development of Pro-Peptide Immunotherapy for Breast Cancer WZ Wei , WAYNE STATE UNIV DETROIT MI - 2002 - apps.dtic.milhttps://apps.dtic.mil/sti/citations/tr/ADA423668 Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for"self" antigens WW Overwijk , DR Surman, K Tsung, NP Restifo - Methods, 1997 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1046202397904618 Development of Pro-Peptide Immunotherapy for Breast Cancer W Wei-Zan, WAYNE STATE UNIV DETROIT MI - 2000., 2000 - apps.dtic.milhttps://apps.dtic.mil/sti/citations/tr/ADA385378 Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins T Sparwasser , RM Vabulas, B Villmow - European journal of , 2000 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/1521-4141(200012)30:12%3C3591::AID-IMMU3591%3E3.0.CO;2-J Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 SJ Dovedi, EJ Cheadle, AL Popple, E Poon - Clinical Cancer , 2017 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/23/18/5514/258969 Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade SJ Dovedi, AL Adlard, G Lipowska-Bhalla, C McKenna - Cancer research, 2014 - AACRhttps://aacrjournals.org/cancerres/article-abstract/74/19/5458/593294 Trafficking of tumor peptide-specific cytotoxic T lymphocytes into the tumor microcirculation S Ali, M Ahmad, J Lynam, RC Rees - International journal of , 2004 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.20113 Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines RH McMahan , JA McWilliams - The Journal of , 2006 - Am Soc Clin Investighttps://www.jci.org/articles/view/26936 The tailless complex polypeptide-1 ring complex of the heat shock protein 60 family facilitates cross-priming of CD8 responses specific for chaperoned peptides RE Vatner, PK Srivastava - The Journal of Immunology, 2010 - journals.aai.orghttps://journals.aai.org/jimmunol/article/185/11/6765/84828 The Tailless Complex Polypeptide-1 Ring RE Vatner, PK Srivastava - 2010 - academia.eduhttps://www.academia.edu/download/89157083/6765.full.pdf Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer NP Restifo , DR Surman, H Zheng, P Palese - Virology, 1998 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0042682298993308 Production of specific antibody and T helper 1-dominant cytokine elicited by dendritic cells genetically modified with an adenovirus vector N Inoue, S Kanaoka, S Yamasaki, S Arii, M Imamura - Immunology letters, 1999 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0165247899001376 uary zyxwvutsrqponmlkjihgfedcbaZYX N DeMartino, J Bevan - J Immunol, 1994 - academia.eduhttps://www.academia.edu/download/107963949/3884.pdf Endoplasmic reticulum aminopeptidase associated with antigen processing defines the composition and structure of MHC class I peptide repertoire in normal and N Blanchard , T Kanaseki, H Escobar - The Journal of , 2010 - journals.aai.orghttps://journals.aai.org/jimmunol/article/184/6/3033/82711 Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model MW Carroll , WW Overwijk , RS Chamberlain - Vaccine, 1997 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X96001958 Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen M Wang , PW Chen, V Bronte - Journal of , 1995 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/abstract/1995/10000/anti_tumor_activity_of_cytotoxic_t_lymphocytes.1.aspx Functional testing of a bicistronic retroviral vector for intracellular peptide production M Duch, A Tolstrup, I Dalum, T Jespersen - , 1999 - Future Sciencehttps://www.future-science.com/doi/pdf/10.2144/99266bm04 In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins M Breloer , B Fleischer, A Bonin - The Journal of Immunology, 1999 - journals.aai.orghttps://journals.aai.org/jimmunol/article/162/6/3141/44233 Proteolytic processing of ovalbumin and beta-galactosidase by the proteasome to a yield antigenic peptides. LR Dick, C Aldrich, SC Jameson - (Baltimore, Md.: 1950 , 1994 - journals.aai.orghttps://journals.aai.org/jimmunol/article-abstract/152/8/3884/27628 Semliki forest virus and Kunjin virus RNA replicons elicit comparable cellular immunity but distinct humoral immunity LL Tannis, A Gauthier, C Evelegh, R Parsons, D Nyholt - Vaccine, 2005 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X05004184 Characterisation of MHC class 1 tumour antigens JR Lill - 2000 - search.proquest.comhttps://search.proquest.com/openview/afa2a2cd7ebbb1be0bb29c138aabd13a/1?pq-origsite=gscholar&cbl=2026366&diss=y Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines J Bramson , K Dayball, C Evelegh, YH Wan , D Page - Gene therapy, 2003 - nature.comhttps://www.nature.com/articles/3301886 In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies I Hoerr, R Obst, HG Rammensee - European journal of , 2000 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/1521-4141(200001)30:1%3C1::AID-IMMU1%3E3.0.CO;2-%23 Interferon-γ ELISPOT Assay for the Quantitative Measurement of Antigen-Specific Murine CD8+ T-Cells GA Cole - Handbook of ELISPOT: Methods and Protocols, 2005 - Springerhttps://link.springer.com/protocol/10.1385/1-59259-903-6:191 Expression levels of stress protein gp96 are not limiting for major histocompatibility complex class I-restricted antigen presentation E Lammert , D Arnold, HG Rammensee - European journal of , 1996 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.1830260423 Influences of transporter associated with antigen processing (TAP) on the repertoire of peptides associated with the endoplasmic reticulum-resident stress protein D Arnold, C Wahl, S Faath, HG Rammensee - The Journal of , 1997 - rupress.orghttps://rupress.org/jem/article-abstract/186/3/461/7232 Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses CB Kemmler , ET Clambey, RM Kedl - The Journal of , 2011 - journals.aai.orghttps://journals.aai.org/jimmunol/article/187/9/4431/39535

Avviso:
I nostri prodotti sono destinati esclusivamente ad uso di laboratorio. Per qualsiasi altro utilizzo, vi preghiamo di contattarci.
Marchio:
Biosynth
Conservazione lunga:
Note:

Proprietà chimiche

MDL:
Punto di fusione:
Punto di ebollizione:
Punto di infiammabilità:
Densità:
Concentrazione:
EINECS:
Merck:
Codice SA:

Informazioni sui pericoli

Numero ONU:
EQ:
Classe:
Indicazioni di pericolo:
Consigli di prudenza:
Vietato trasportare in aereo:
Informazioni sui pericoli:
Gruppo di imballaggio:
LQ:

Richiesta tecnica su: 3D-PP45176 H-TPHPARIGL-OH

Si prega di utilizzare piuttosto il carrello per richiedere un preventivo o un ordine

Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.

* Campi obbligatori
Benvenuto su CymitQuimica!Utilizziamo i cookie per migliorare la tua visita. Non includiamo pubblicità.

Consulta la nostra Politica sui Cookie per maggiori dettagli o regola le tue preferenze in "Configura".